TY - JOUR
T1 - Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck
T2 - Results of a Phase I Dose-Escalation Trial
AU - Heron, Dwight E.
AU - Ferris, Robert L.
AU - Karamouzis, Michalis
AU - Andrade, Regiane S.
AU - Deeb, Erin L.
AU - Burton, Steven
AU - Gooding, William E.
AU - Branstetter, Barton F.
AU - Mountz, James M.
AU - Johnson, Jonas T.
AU - Argiris, Athanassios
AU - Grandis, Jennifer R.
AU - Lai, Stephen Y.
PY - 2009/12/1
Y1 - 2009/12/1
N2 - Purpose: To evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN). Patients and Methods: In this Phase I dose-escalation clinical trial, 25 patients were treated in five dose tiers up to 44 Gy, administered in 5 fractions over a 2-week course. Response was assessed according to the Response Evaluation Criteria in Solid Tumors and [18F]-fluorodeoxyglucose standardized uptake value change on positron emission tomography-computed tomography (PET-CT). Results: No Grade 3/4 or dose-limiting toxicities occurred. Four patients had Grade 1/2 acute toxicities. Four objective responses were observed, for a response rate of 17% (95% confidence interval 2%-33%). The maximum duration of response was 4 months. Twelve patients had stable disease. Median time to disease progression was 4 months, and median overall survival was 6 months. Self-reported quality of life was not significantly affected by treatment. Fluorodeoxyglucose PET was a more sensitive early-measure response to treatment than CT volume changes. Conclusion: Reirradiation up to 44 Gy using SBRT is well tolerated in the acute setting and warrants further evaluation in combination with conventional and targeted therapies.
AB - Purpose: To evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN). Patients and Methods: In this Phase I dose-escalation clinical trial, 25 patients were treated in five dose tiers up to 44 Gy, administered in 5 fractions over a 2-week course. Response was assessed according to the Response Evaluation Criteria in Solid Tumors and [18F]-fluorodeoxyglucose standardized uptake value change on positron emission tomography-computed tomography (PET-CT). Results: No Grade 3/4 or dose-limiting toxicities occurred. Four patients had Grade 1/2 acute toxicities. Four objective responses were observed, for a response rate of 17% (95% confidence interval 2%-33%). The maximum duration of response was 4 months. Twelve patients had stable disease. Median time to disease progression was 4 months, and median overall survival was 6 months. Self-reported quality of life was not significantly affected by treatment. Fluorodeoxyglucose PET was a more sensitive early-measure response to treatment than CT volume changes. Conclusion: Reirradiation up to 44 Gy using SBRT is well tolerated in the acute setting and warrants further evaluation in combination with conventional and targeted therapies.
KW - Head-and-neck cancer
KW - Head-and-neck squamous cell carcinoma
KW - PET-CT
KW - Reirradiation
KW - Stereotactic body radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=71649101387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71649101387&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2008.12.075
DO - 10.1016/j.ijrobp.2008.12.075
M3 - Article
C2 - 19464819
AN - SCOPUS:71649101387
VL - 75
SP - 1493
EP - 1500
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
SN - 0360-3016
IS - 5
ER -